Faculty, Staff and Student Publications
Language
English
Publication Date
2-1-2025
Journal
Nature Cancer
DOI
10.1038/s43018-024-00896-w
PMID
39789182
PMCID
PMC12121501
PubMedCentral® Posted Date
2-1-2026
PubMedCentral® Full Text Version
Author MSS
Abstract
Immune checkpoint inhibitors can lead to 'exceptional', durable responses in a subset of persons. However, the molecular basis of exceptional response (ER) to immunotherapy in metastatic clear cell renal cell carcinoma (mccRCC) has not been well characterized. Here we analyzed pretherapy genomic and transcriptomic data in treatment-naive persons with mccRCC treated with standard-of-care immunotherapies: (1) combination of programmed cell death protein and ligand 1 (PD1/PDL1) and cytotoxic T lymphocyte-associated protein 4 inhibitors (IO/IO) or (2) combination of PD1/PDL1 and vascular endothelial growth factor (VEGF) receptor inhibitors (IO/VEGF). In the IO/IO cohort, clonal neoantigen load was significantly higher in persons with ER. In the IO/VEGF cohort, ER participants displayed strong enrichment of B cell receptor signaling-related pathways, tertiary lymphoid structure (TLS) signatures and evidence of increased metabolic activity. Our results suggest that ER may be related to clonal neoantigen-driven cytotoxic T cell responses and TLS formation in tumor microenvironments. Therapeutic combinations that elicit both T cell-directed and B cell-directed antitumor immunity may be important to achieve exceptional benefit to IO-based treatment in ccRCC.
Keywords
Humans, Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Kidney Neoplasms, Female, Male, Middle Aged, Immunotherapy, B7-H1 Antigen, Aged, Programmed Cell Death 1 Receptor, Tumor Microenvironment
Published Open-Access
yes
Recommended Citation
Jammihal, Tejas; Saliby, Renee Maria; Labaki, Chris; et al., "Immunogenomic Determinants of Exceptional Response to Immune Checkpoint Inhibition in Renal Cell Carcinoma" (2025). Faculty, Staff and Student Publications. 5446.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5446
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons